ReviewNanomaterials (Basel, Switzerland)2021
Novel Perspectives towards RNA-Based Nano-Theranostic Approaches for Cancer Management.
Review in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Multimodal strategies for diagnosing and treating thyroid cancer: Advances in basic and clinical research.Translational oncology · 2026Review
- Toward nanomedicine-enabled RNA therapeutics for Alzheimer's disease.Molecular neurodegeneration advances · 2026Review
- Biomedical Applications of Carbon-Based Nanomaterials: Exploring Recent Advances in Therapeutics, Diagnostics, and Tissue Engineering.Advanced pharmaceutical bulletin · 2025Review
- Nanotechnology-based drug delivery system for the diagnosis and treatment of ovarian cancer.Discover oncology · 2025Review
- Unlocking the Potential of RNA Nanoparticles: A Breakthrough Approach to Overcoming Challenges in Colon Cancer Treatment.Current pharmaceutical biotechnology · 2025Review
- Recent advances in the bench-to-bedside translation of cancer nanomedicines.Acta pharmaceutica Sinica. B · 2025Review
- Patent landscape of nanotechnology - based nucleic acid delivery systems for breast cancer therapies.Frontiers in oncology · 2025Article
- Role of non-coding RNA through nanomedicine: the novel therapeutic and diagnostic approaches.BioImpacts : BI · 2025Review
- Advances in nanomedicine and delivery systems for gastric cancer research.Frontiers in bioengineering and biotechnology · 2025Review
- Iron-based compounds coordinated with phospho-polymers as biocompatible probes for dualScientific reports · 2024Article
- Recent Advances in Mesoporous Silica Nanoparticles Delivering siRNA for Cancer Treatment.Pharmaceutics · 2023Review
- An update in the applications of exosomes in cancer theranostics: from research to clinical trials.Journal of cancer research and clinical oncology · 2023Review
- Effective, Rapid, and Small-Scale Bioconjugation and Purification of "Clicked" Small-Molecule DNA Oligonucleotide for Nucleic Acid Nanoparticle Functionalization.International journal of molecular sciences · 2023Article
- Nanomaterials for Drug Delivery and Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2023Article
- Nanoparticles and Nanomaterials-Based Recent Approaches in Upgraded Targeting and Management of Cancer: A Review.Cancers · 2022Review
- Optical diagnostic imaging and therapy for thyroid cancer.Materials today. Bio · 2022Review
- Nanotechnological approaches for diagnosis and treatment of ovarian cancer: a review of recent trends.Drug delivery · 2022Review
- siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.Cell biology international · 2022Review
- Review
- Surface Engineering of Nanomaterials with Polymers, Biomolecules, and Small Ligands for Nanomedicine.Materials (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In the fight against cancer, early diagnosis is critical for effective treatment. Traditional cancer diagnostic technologies, on the other hand, have limitations that make early detection difficult. Therefore, multi-functionalized nanoparticles (NPs) and nano-biosensors have revolutionized the era of cancer diagnosis and treatment for targeted action via attaching specified and biocompatible ligands to target the tissues, which are highly over-expressed in certain types of cancers. Advancements in multi-functionalized NPs can be achieved via modifying molecular genetics to develop personalized and targeted treatments based on RNA interference. Modification in RNA therapies utilized small RNA subunits in the form of small interfering RNAs (siRNA) for overexpressing the specific genes of, most commonly, breast, colon, gastric, cervical, and hepatocellular cancer. RNA-conjugated nanomaterials appear to be the gold standard for preventing various malignant tumors through focused diagnosis and delivering to a specific tissue, resulting in cancer cells going into programmed death. The latest advances in RNA nanotechnology applications for cancer diagnosis and treatment are summarized in this review.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.